{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:04:42Z","timestamp":1791212682417,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Ratchadaphiseksomphot Endowment Fund"},{"DOI":"10.13039\/501100002842","name":"Chiang Mai University, Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jmgm.2019.03.006","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T06:34:48Z","timestamp":1552286088000},"page":"122-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3\/4A protease: A molecular dynamics simulation"],"prefix":"10.1016","volume":"89","author":[{"given":"Jirayu","family":"Kammarabutr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panupong","family":"Mahalapbutr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodee","family":"Nutho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawee","family":"Kungwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyada","family":"Rungrotmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jmgm.2019.03.006_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.addr.2007.04.014","article-title":"Hepatitis C viral life cycle","volume":"59","author":"Suzuki","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jmgm.2019.03.006_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.pmbts.2014.10.003","article-title":"The mechanism of HCV entry into host cells","volume":"129","author":"Douam","year":"2015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.jmgm.2019.03.006_bib3","series-title":"Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection","author":"Organization","year":"2016"},{"issue":"1 Suppl","key":"10.1016\/j.jmgm.2019.03.006_bib4","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J.\u00a0Hepatol."},{"issue":"1","key":"10.1016\/j.jmgm.2019.03.006_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jmgm.2019.03.006_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virusres.2007.10.003","article-title":"A\u00a0wide range of NS3\/4A protease catalytic efficiencies in HCV-infected individuals","volume":"131","author":"Franco","year":"2008","journal-title":"Virus Res."},{"issue":"13","key":"10.1016\/j.jmgm.2019.03.006_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jmgm.2019.03.006_bib8","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.bmcl.2012.01.017","article-title":"Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3\/4A protease","volume":"22","author":"Sheng","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmgm.2019.03.006_bib9","series-title":"Hepatitis C Viruses: Genomes and Molecular Biology","article-title":"HCV genome and life cycle","author":"Chevaliez","year":"2006"},{"key":"10.1016\/j.jmgm.2019.03.006_bib10","series-title":"Hepatitis C Viruses: Genomes and Molecular Biology","article-title":"HCV NS2\/3 protease","author":"Welbourn","year":"2006"},{"issue":"1","key":"10.1016\/j.jmgm.2019.03.006_bib11","first-page":"22","article-title":"The discovery and development of boceprevir: a novel, first-generation inhibitor of the hepatitis C virus NS3\/4a serine protease","volume":"1","author":"Howe","year":"2013","journal-title":"J.\u00a0Clin. Transl. Hepatol."},{"issue":"3","key":"10.1016\/j.jmgm.2019.03.006_bib12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.50.3.1013-1020.2006","article-title":"SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells","volume":"50","author":"Malcolm","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.jmgm.2019.03.006_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.tips.2012.03.012","article-title":"Discovery of boceprevir, a direct-acting NS3\/4A protease inhibitor for treatment of chronic hepatitis C infections","volume":"33","author":"Venkatraman","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.jmgm.2019.03.006_bib14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nbt.2020","article-title":"Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus","volume":"29","author":"Kwong","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.jmgm.2019.03.006_bib15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jmgm.2019.03.006_bib16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In\u00a0vitro and in\u00a0vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Pilot-Matias","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.jmgm.2019.03.006_bib17","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In\u00a0vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.jmgm.2019.03.006_bib18","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1128\/AAC.01058-08","article-title":"In\u00a0vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor","volume":"53","author":"Lin","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jmgm.2019.03.006_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","article-title":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics","volume":"99","author":"Lawitz","year":"2013","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.jmgm.2019.03.006_bib20","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1021\/jm9015526","article-title":"Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3\/4a protease inhibitor","volume":"53","author":"McCauley","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"issue":"8","key":"10.1016\/j.jmgm.2019.03.006_bib21","first-page":"951","article-title":"Danoprevir, a small-molecule NS3\/4A protease inhibitor for the potential oral treatment of HCV infection","volume":"11","author":"Deutsch","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.jmgm.2019.03.006_bib22","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/jm400164c","article-title":"Discovery of danoprevir (ITMN-191\/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3\/4A protease","volume":"57","author":"Jiang","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"issue":"8","key":"10.1016\/j.jmgm.2019.03.006_bib23","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.jmgm.2019.03.006_bib24","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jmgm.2019.03.006_bib25","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","article-title":"Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.jmgm.2019.03.006_bib26","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1021\/jm500297k","article-title":"The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection","volume":"57","author":"Scola","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"issue":"1","key":"10.1016\/j.jmgm.2019.03.006_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/AAC.05166-11","article-title":"In\u00a0vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335","volume":"56","author":"Lagace","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.jmgm.2019.03.006_bib28","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.jmgm.2019.03.006_bib29","doi-asserted-by":"crossref","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.jmgm.2019.03.006_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/AAC.00487-13","article-title":"Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451","volume":"58","author":"Yang","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmgm.2019.03.006_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist. Updates"},{"issue":"6","key":"10.1016\/j.jmgm.2019.03.006_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14656566.2018.1454428","article-title":"Protease inhibitor therapy for hepatitis C virus-infection","volume":"19","author":"de Leuw","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"issue":"9","key":"10.1016\/j.jmgm.2019.03.006_bib33","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1039\/C5MB00394F","article-title":"Exploring resistance mechanisms of HCV NS3\/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations","volume":"11","author":"Guan","year":"2015","journal-title":"Mol. Biosyst."},{"issue":"10","key":"10.1016\/j.jmgm.2019.03.006_bib34","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.bbagen.2012.06.001","article-title":"Understanding the drug resistance mechanism of hepatitis C virus NS3\/4A to ITMN-191 due to R155K, A156V, D168A\/E mutations: a computational study","volume":"1820","author":"Pan","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.jmgm.2019.03.006_bib35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.antiviral.2011.11.007","article-title":"Molecular modeling study on the resistance mechanism of HCV NS3\/4A serine protease mutants R155K, A156V and D168A to TMC435","volume":"93","author":"Xue","year":"2012","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.jmgm.2019.03.006_bib36","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/cb5006118","article-title":"Structural analysis of asunaprevir resistance in HCV NS3\/4A protease","volume":"9","author":"Soumana","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jmgm.2019.03.006_bib37","series-title":"Dassault Syst\u00e8mes BIOVIA, Discovery Studio, 3.5, San Diego","author":"Syst\u00e8mes","year":"2012"},{"key":"10.1016\/j.jmgm.2019.03.006_bib38","doi-asserted-by":"crossref","first-page":"W665","DOI":"10.1093\/nar\/gkh381","article-title":"PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations","volume":"32","author":"Dolinsky","year":"2004","journal-title":"Nucl. Acids Res."},{"issue":"2","key":"10.1016\/j.jmgm.2019.03.006_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/wcms.1121","article-title":"An overview of the Amber biomolecular simulation package","volume":"3","author":"Salomon-Ferrer","year":"2013","journal-title":"Wiley Interdiscipl. Rev. Comput. Mol. Sci."},{"key":"10.1016\/j.jmgm.2019.03.006_bib40","series-title":"Amber 14","author":"Case","year":"2014"},{"key":"10.1016\/j.jmgm.2019.03.006_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jmgm.2017.11.006","article-title":"Molecular insights into inclusion complexes of mansonone E and H enantiomers with various beta-cyclodextrins","volume":"79","author":"Mahalapbutr","year":"2018","journal-title":"J.\u00a0Mol. Graph. Model."},{"issue":"4","key":"10.1016\/j.jmgm.2019.03.006_bib42","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1021\/ci400605a","article-title":"Key binding and susceptibility of NS3\/4A serine protease inhibitors against hepatitis C virus","volume":"54","author":"Meeprasert","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model."},{"issue":"10","key":"10.1016\/j.jmgm.2019.03.006_bib43","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10822-016-9981-5","article-title":"Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM\/PB(GB)SA study","volume":"30","author":"Phanich","year":"2016","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"issue":"19","key":"10.1016\/j.jmgm.2019.03.006_bib44","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.1073\/pnas.0408037102","article-title":"Potential energy functions for atomic-level simulations of water and organic and biomolecular systems","volume":"102","author":"Jorgensen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.jmgm.2019.03.006_bib45","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/jcc.540130805","article-title":"Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models","volume":"13","author":"Miyamoto","year":"1992","journal-title":"J.\u00a0Comput. Chem."},{"issue":"12","key":"10.1016\/j.jmgm.2019.03.006_bib46","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1021\/acs.jctc.5b00648","article-title":"A\u00a0stochastic algorithm for the isobaric-isothermal ensemble with Ewald summations for all long range forces","volume":"11","author":"Di Pierro","year":"2015","journal-title":"J.\u00a0Chem. Theory Comput."},{"key":"10.1016\/j.jmgm.2019.03.006_bib47","doi-asserted-by":"crossref","first-page":"183918","DOI":"10.1155\/2015\/183918","article-title":"Molecular dynamics, Monte Carlo simulations, and Langevin dynamics: a computational review","volume":"2015","author":"Paquet","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.jmgm.2019.03.006_bib48","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.3762\/bjoc.10.296","article-title":"Binding mode and free energy prediction of fisetin\/beta-cyclodextrin inclusion complexes","volume":"10","author":"Nutho","year":"2014","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.jmgm.2019.03.006_bib49","first-page":"1","article-title":"Computational screening of fatty acid synthase inhibitors against thioesterase domain","author":"Panman","year":"2017","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"issue":"36","key":"10.1016\/j.jmgm.2019.03.006_bib50","doi-asserted-by":"crossref","first-page":"11850","DOI":"10.1021\/jacs.6b06454","article-title":"Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3\/4a protease","volume":"138","author":"Soumana","year":"2016","journal-title":"J.\u00a0Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.jmgm.2019.03.006_bib51","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1529\/biophysj.107.120501","article-title":"Molecular dynamics and principal components analysis of human telomeric quadruplex multimers","volume":"95","author":"Haider","year":"2008","journal-title":"Biophys. J."},{"issue":"12","key":"10.1016\/j.jmgm.2019.03.006_bib52","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1039\/C6MB00610H","article-title":"Effect of D168V mutation in NS3\/4A HCV protease on susceptibilities of faldaprevir and danoprevir","volume":"12","author":"Meeprasert","year":"2016","journal-title":"Mol. Biosyst."},{"issue":"5","key":"10.1016\/j.jmgm.2019.03.006_bib53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1139\/bcb-2014-0039","article-title":"Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3\/4A protease","volume":"92","author":"Wang","year":"2014","journal-title":"Biochem. Cell Biol."},{"issue":"2","key":"10.1016\/j.jmgm.2019.03.006_bib54","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/ci400060j","article-title":"Computational study on the drug resistance mechanism against HCV NS3\/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis","volume":"54","author":"Xue","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model."}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326318309574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326318309574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:00:38Z","timestamp":1761080438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326318309574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":54,"alternative-id":["S1093326318309574"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2019.03.006","relation":{},"ISSN":["1093-3263"],"issn-type":[{"value":"1093-3263","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3\/4A protease: A molecular dynamics simulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2019.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}